Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Accro Bioscience raises $50m Series C to advance AC-101 and immune-mediated disease pipeline
Ulcerative colitis needs safer oral options. Accro’s OrbiMed-led raise puts RIPK2 inhibition under a bigger clinical spotlight.
A $260.7m COPD market is opening up. Can Lupin Limited (NSE: LUPIN) turn approval into revenue?
A COPD generic opens a $260.7M U.S. door for Lupin Limited. The bigger test is launch timing, competition, and margin discipline.
BioMarin’s BMN 401 setback raises regulatory questions after ENPP1 deficiency trial meets only one endpoint
BioMarin moved the biomarker, not the rickets score. BMN 401 now tests how much regulators will accept in ultra-rare disease trials.
Virtual Science AI launches Medical Competitor AI as pharma launch teams demand sharper competitor intelligence
Pharma launch teams need sharper competitor intelligence. Virtual Science AI is turning medical activity tracking into an AI workflow.
What the latest UTOPIA trial data reveal about UGN-103’s competitive position in LG-IR-NMIBC
UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Discover what it means for NMIBC competition and growth.
What the RIDGE-1 interim results reveal about the future of cardiac gene therapy in ARVC
Could TN-401 reshape inherited heart disease treatment? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
Regeneron Pharmaceuticals’ LAG-3 gamble stumbles as Keytruda remains hard to beat in melanoma
Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
ImmunityBio targets U.S. BCG shortage with exclusive Tokyo-172 agreement and FDA pathway plan
BCG supply is still a U.S. bladder cancer bottleneck. ImmunityBio’s Tokyo deal could widen access, if regulators move with it.
AstraZeneca, Daiichi Sankyo secure FDA approval for Enhertu in two early breast cancer indications
Enhertu is moving from late-stage control to early-stage cure. AstraZeneca and Daiichi Sankyo now face the bigger test: adoption.
TuHURA Biosciences extends runway into 2028 as HURA investors wait for Merkel cell carcinoma data
TuHURA has bought time with a $50m facility. The harder test is whether IFx-2.0 can deliver before HURA investors lose patience.